NAMS Menopause Exam Q-Bank – Complete Certified Menopause
Practitioner Practice Questions 2026–2028 | Practice Questions &
Answers | Complete Study Guide
Prepare for the NAMS Certified Menopause Practitioner examination with this comprehensive
study guide featuring original practice questions, detailed answer explanations, and exam-
focused review material. Topics include menopause physiology, hormone therapy, nonhormonal
treatment options, vasomotor symptoms, genitourinary syndrome of menopause (GSM),
osteoporosis prevention, cardiovascular health, sexual health, patient counseling, and evidence-
based menopause management. Designed to strengthen clinical knowledge and improve
certification readiness, this guide is ideal for healthcare professionals preparing for the Certified
Menopause Practitioner examination
Q1. A 52-year-old woman presents with severe vasomotor symptoms. She has a
history of an intact uterus and no contraindications to hormone therapy.
According to current evidence-based guidelines, what is the primary clinical
reason for including a progestogen in her systemic hormone therapy regimen?
A) To provide additional relief from hot flashes and night sweats
B) To protect the endometrium against estrogen-induced hyperplasia and
adenocarcinoma
C) To lower the systemic risk of deep vein thrombosis
D) To prevent age-related bone mineral density loss
Answer: B) To protect the endometrium against estrogen-induced hyperplasia
and adenocarcinoma
Rationale: Systemic estrogen therapy given without a progestogen (unopposed
estrogen) to a woman with an intact uterus significantly increases the risk of endometrial
hyperplasia and carcinoma. A progestogen or selective estrogen receptor modulator
(SERM) must be co-administered to neutralize this risk.
Q2. During a clinical consultation, a 54-year-old woman requests non-hormonal
management for moderate-to-severe vasomotor symptoms. Which of the
following centrally acting non-hormonal medications is specifically approved by
the FDA for this indication?
,A) Paroxetine mesylate (7.5 mg daily)
B) Venlafaxine ER (150 mg daily)
C) Fluoxetine hydrochloride (40 mg daily)
D) Amitriptyline (25 mg daily)
Answer: A) Paroxetine mesylate (7.5 mg daily)
Rationale: Low-dose paroxetine mesylate (7.5 mg/day) was the first non-hormonal
medication specifically FDA-approved for treating moderate-to-severe vasomotor
symptoms associated with menopause. While other SSRIs and SNRIs (like venlafaxine)
are utilized off-label, paroxetine mesylate holds formal regulatory approval.
Q3. A 58-year-old woman who underwent a total abdominal hysterectomy and
bilateral salpingo-oophorectomy five years ago presents with severe hot flashes.
She has no personal or family history of breast cancer or cardiovascular disease.
What is the most appropriate systemic hormone therapy for this patient?
A) Combined transdermal estradiol and oral micronized progesterone
B) Estrogen-only therapy (systemic oral or transdermal estradiol)
C) Conjugated estrogens combined with bazedoxifene
D) Intermittent vaginal estradiol cream
Answer: B) Estrogen-only therapy (systemic oral or transdermal estradiol)
Rationale: Women who have undergone a hysterectomy do not require endometrial
protection. Therefore, they should be prescribed estrogen-only therapy for systemic
symptoms. Adding a progestogen is unnecessary and introduces potential unfavorable
changes to breast tissue risk profiles.
Q4. When analyzing data from the Women's Health Initiative (WHI), which of the
following statements correctly identifies a key statistical difference in breast
cancer outcomes between the two primary study groups?
A) The estrogen-alone arm showed an increased risk of breast cancer compared to
placebo.
B) The conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA)
arm demonstrated a statistically significant increase in the risk of invasive breast
cancer.
C) Both groups showed identical decreases in breast cancer outcomes.
D) The combination arm showed a lower risk of stroke than the estrogen-alone arm.
,Answer: B) The conjugated equine estrogens (CEE) plus medroxyprogesterone
acetate (MPA) arm demonstrated a statistically significant increase in the risk of
invasive breast cancer.
Rationale: The WHI trial established that combination therapy (CEE + MPA) increased
the risk of invasive breast cancer after an average of 5.6 years of use. In contrast, the
estrogen-alone (CEE) arm for women with a prior hysterectomy demonstrated a non-
significant decrease or neutral trend in breast cancer risk during the intervention period.
Q5. A 51-year-old woman presents with severe vulvovaginal atrophy
(Genitourinary Syndrome of Menopause, or GSM) causing dyspareunia. She has
no vasomotor symptoms and no contraindications to estrogen. What is the
preferred first-line prescription therapy according to NAMS guidelines?
A) High-dose oral conjugated estrogens
B) Low-dose local vaginal estrogen therapy (ring, tablet, or cream)
C) Systemic transdermal estradiol patch
D) Oral micronized progesterone monotherapy
Answer: B) Low-dose local vaginal estrogen therapy (ring, tablet, or cream)
Rationale: For women experiencing isolated genitourinary symptoms without systemic
vasomotor complaints, low-dose local vaginal estrogen therapy is preferred. This
delivery method maximizes targeted tissue efficacy while minimizing systemic
absorption and associated risks.
Q6. A 53-year-old menopausal patient with a history of hypertension and a body
mass index (BMI) of 34 kg/m² requires systemic estrogen therapy for debilitating
hot flashes. Which route of administration is preferred to minimize the risk of
venous thromboembolism (VTE)?
A) Oral administration
B) Transdermal administration
C) Subcutaneous pellet implantation
D) Intramuscular injection
Answer: B) Transdermal administration
Rationale: Transdermal estrogen delivery bypasses the first-pass hepatic metabolism,
avoiding the up-regulation of clotting factors and sex hormone-binding globulin (SHBG).
Observational data demonstrate that transdermal estradiol does not increase VTE risk,
making it safer for obese or hypertensive patients.
, Q7. Which endocrine changes are highly characteristic of the epidemiological
transition from late perimenopause to final postmenopause?
A) Significantly elevated progesterone and decreased luteinizing hormone (LH)
B) Marked elevation of follicle-stimulating hormone (FSH) accompanied by a profound
decline in estradiol levels
C) Elevated antimüllerian hormone (AMH) and increased inhibin B
D) Decreased FSH and increased estrone
Answer: B) Marked elevation of follicle-stimulating hormone (FSH) accompanied
by a profound decline in estradiol levels
Rationale: As the ovarian follicular pool becomes depleted during menopause, the loss
of negative feedback from inhibin and estradiol causes a dramatic, sustained rise in
systemic FSH levels, while circulating estradiol concentrations drop significantly.
Q8. A 55-year-old postmenopausal woman with a T-score of –2.7 at the lumbar
spine is diagnosed with osteoporosis. She also suffers from moderate hot
flashes. She wants a single therapeutic option that treats symptoms and
stabilizes bone density. Which of the following is a tissue-selective estrogen
complex (TSEC) approved for this dual purpose?
A) Conjugated estrogens combined with bazedoxifene
B) Estradiol combined with drospirenone
C) Ethinyl estradiol combined with norethindrone
D) Raloxifene monotherapy
Answer: A) Conjugated estrogens combined with bazedoxifene
Rationale: The combination of conjugated equine estrogens (CEE) and the SERM
bazedoxifene creates a TSEC. Bazedoxifene acts as an estrogen antagonist in the
endometrium (obviating the need for a progestogen) while acting as an agonist in bone
tissue and maintaining CEE’s efficacy against hot flashes.
Q9. For a postmenopausal woman experiencing moderate dyspareunia from
vulvovaginal atrophy, which non-estrogen, oral selective estrogen receptor
modulator (SERM) is FDA-approved as a daily systemic treatment option?
A) Tamoxifen
B) Ospemifene
Practitioner Practice Questions 2026–2028 | Practice Questions &
Answers | Complete Study Guide
Prepare for the NAMS Certified Menopause Practitioner examination with this comprehensive
study guide featuring original practice questions, detailed answer explanations, and exam-
focused review material. Topics include menopause physiology, hormone therapy, nonhormonal
treatment options, vasomotor symptoms, genitourinary syndrome of menopause (GSM),
osteoporosis prevention, cardiovascular health, sexual health, patient counseling, and evidence-
based menopause management. Designed to strengthen clinical knowledge and improve
certification readiness, this guide is ideal for healthcare professionals preparing for the Certified
Menopause Practitioner examination
Q1. A 52-year-old woman presents with severe vasomotor symptoms. She has a
history of an intact uterus and no contraindications to hormone therapy.
According to current evidence-based guidelines, what is the primary clinical
reason for including a progestogen in her systemic hormone therapy regimen?
A) To provide additional relief from hot flashes and night sweats
B) To protect the endometrium against estrogen-induced hyperplasia and
adenocarcinoma
C) To lower the systemic risk of deep vein thrombosis
D) To prevent age-related bone mineral density loss
Answer: B) To protect the endometrium against estrogen-induced hyperplasia
and adenocarcinoma
Rationale: Systemic estrogen therapy given without a progestogen (unopposed
estrogen) to a woman with an intact uterus significantly increases the risk of endometrial
hyperplasia and carcinoma. A progestogen or selective estrogen receptor modulator
(SERM) must be co-administered to neutralize this risk.
Q2. During a clinical consultation, a 54-year-old woman requests non-hormonal
management for moderate-to-severe vasomotor symptoms. Which of the
following centrally acting non-hormonal medications is specifically approved by
the FDA for this indication?
,A) Paroxetine mesylate (7.5 mg daily)
B) Venlafaxine ER (150 mg daily)
C) Fluoxetine hydrochloride (40 mg daily)
D) Amitriptyline (25 mg daily)
Answer: A) Paroxetine mesylate (7.5 mg daily)
Rationale: Low-dose paroxetine mesylate (7.5 mg/day) was the first non-hormonal
medication specifically FDA-approved for treating moderate-to-severe vasomotor
symptoms associated with menopause. While other SSRIs and SNRIs (like venlafaxine)
are utilized off-label, paroxetine mesylate holds formal regulatory approval.
Q3. A 58-year-old woman who underwent a total abdominal hysterectomy and
bilateral salpingo-oophorectomy five years ago presents with severe hot flashes.
She has no personal or family history of breast cancer or cardiovascular disease.
What is the most appropriate systemic hormone therapy for this patient?
A) Combined transdermal estradiol and oral micronized progesterone
B) Estrogen-only therapy (systemic oral or transdermal estradiol)
C) Conjugated estrogens combined with bazedoxifene
D) Intermittent vaginal estradiol cream
Answer: B) Estrogen-only therapy (systemic oral or transdermal estradiol)
Rationale: Women who have undergone a hysterectomy do not require endometrial
protection. Therefore, they should be prescribed estrogen-only therapy for systemic
symptoms. Adding a progestogen is unnecessary and introduces potential unfavorable
changes to breast tissue risk profiles.
Q4. When analyzing data from the Women's Health Initiative (WHI), which of the
following statements correctly identifies a key statistical difference in breast
cancer outcomes between the two primary study groups?
A) The estrogen-alone arm showed an increased risk of breast cancer compared to
placebo.
B) The conjugated equine estrogens (CEE) plus medroxyprogesterone acetate (MPA)
arm demonstrated a statistically significant increase in the risk of invasive breast
cancer.
C) Both groups showed identical decreases in breast cancer outcomes.
D) The combination arm showed a lower risk of stroke than the estrogen-alone arm.
,Answer: B) The conjugated equine estrogens (CEE) plus medroxyprogesterone
acetate (MPA) arm demonstrated a statistically significant increase in the risk of
invasive breast cancer.
Rationale: The WHI trial established that combination therapy (CEE + MPA) increased
the risk of invasive breast cancer after an average of 5.6 years of use. In contrast, the
estrogen-alone (CEE) arm for women with a prior hysterectomy demonstrated a non-
significant decrease or neutral trend in breast cancer risk during the intervention period.
Q5. A 51-year-old woman presents with severe vulvovaginal atrophy
(Genitourinary Syndrome of Menopause, or GSM) causing dyspareunia. She has
no vasomotor symptoms and no contraindications to estrogen. What is the
preferred first-line prescription therapy according to NAMS guidelines?
A) High-dose oral conjugated estrogens
B) Low-dose local vaginal estrogen therapy (ring, tablet, or cream)
C) Systemic transdermal estradiol patch
D) Oral micronized progesterone monotherapy
Answer: B) Low-dose local vaginal estrogen therapy (ring, tablet, or cream)
Rationale: For women experiencing isolated genitourinary symptoms without systemic
vasomotor complaints, low-dose local vaginal estrogen therapy is preferred. This
delivery method maximizes targeted tissue efficacy while minimizing systemic
absorption and associated risks.
Q6. A 53-year-old menopausal patient with a history of hypertension and a body
mass index (BMI) of 34 kg/m² requires systemic estrogen therapy for debilitating
hot flashes. Which route of administration is preferred to minimize the risk of
venous thromboembolism (VTE)?
A) Oral administration
B) Transdermal administration
C) Subcutaneous pellet implantation
D) Intramuscular injection
Answer: B) Transdermal administration
Rationale: Transdermal estrogen delivery bypasses the first-pass hepatic metabolism,
avoiding the up-regulation of clotting factors and sex hormone-binding globulin (SHBG).
Observational data demonstrate that transdermal estradiol does not increase VTE risk,
making it safer for obese or hypertensive patients.
, Q7. Which endocrine changes are highly characteristic of the epidemiological
transition from late perimenopause to final postmenopause?
A) Significantly elevated progesterone and decreased luteinizing hormone (LH)
B) Marked elevation of follicle-stimulating hormone (FSH) accompanied by a profound
decline in estradiol levels
C) Elevated antimüllerian hormone (AMH) and increased inhibin B
D) Decreased FSH and increased estrone
Answer: B) Marked elevation of follicle-stimulating hormone (FSH) accompanied
by a profound decline in estradiol levels
Rationale: As the ovarian follicular pool becomes depleted during menopause, the loss
of negative feedback from inhibin and estradiol causes a dramatic, sustained rise in
systemic FSH levels, while circulating estradiol concentrations drop significantly.
Q8. A 55-year-old postmenopausal woman with a T-score of –2.7 at the lumbar
spine is diagnosed with osteoporosis. She also suffers from moderate hot
flashes. She wants a single therapeutic option that treats symptoms and
stabilizes bone density. Which of the following is a tissue-selective estrogen
complex (TSEC) approved for this dual purpose?
A) Conjugated estrogens combined with bazedoxifene
B) Estradiol combined with drospirenone
C) Ethinyl estradiol combined with norethindrone
D) Raloxifene monotherapy
Answer: A) Conjugated estrogens combined with bazedoxifene
Rationale: The combination of conjugated equine estrogens (CEE) and the SERM
bazedoxifene creates a TSEC. Bazedoxifene acts as an estrogen antagonist in the
endometrium (obviating the need for a progestogen) while acting as an agonist in bone
tissue and maintaining CEE’s efficacy against hot flashes.
Q9. For a postmenopausal woman experiencing moderate dyspareunia from
vulvovaginal atrophy, which non-estrogen, oral selective estrogen receptor
modulator (SERM) is FDA-approved as a daily systemic treatment option?
A) Tamoxifen
B) Ospemifene
